Genetic signature of prostate cancer resistant to optimized hK2 targeted alpha-particle therapy
M. Bicak, K. Lueckerath, T. Kalidindi, S.-E. Strand, M. Morris, C. Radu, R. Damoiseaux, N. Peekhaus, A. Ho, D. V. Veach, A.-C. Malmborg Hager, S. M. Larson, H. Lilja, M. R. McDevitt, R. J. Klein, D. Ulmert
The paper evaluates enhanced alpha-radioimmunotherapy for prostate cancer using [225Ac]hu11B6-IgG3 and analyzes genomic changes in resistant tumors.
bioRxiv · Sep 2, 2019Cancer Biology